Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, IDYA, PRAX, OLMA, CDTX, and represent 37.57% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: PRAX (+$74M), TERN (+$30M), IDYA (+$30M), TNGX (+$29M), IMVT (+$28M), RCUS (+$25M), MLTX (+$23M), ACAD (+$23M), RVMD (+$20M), CYTK (+$19M).
- Started 24 new stock positions in CRVS, IMTX, NERV, CLDX, CGON, IBIO, DBVT, ACAD, MIRM, PTN. VOR, CYTK, IMMX, TERN, RCUS, NAMS, KNSA, NGNE, DAWN, TYRA, MLTX, ORIC, NRIX, SLNO.
- Reduced shares in these 10 stocks: AKRO (-$57M), ARVN (-$48M), DYN (-$23M), PTGX (-$20M), VSTM (-$18M), GPCR (-$17M), CDTX (-$14M), KROS (-$13M), MAZE (-$12M), DSGN (-$11M).
- Sold out of its positions in AKRO, ALEC, ARVN, Astria Therapeutics, COGT, ESPR, EPRX, IMRX, KROS, LRMR. PEPG, PTGX, SRRK.
- Logos Global Management was a net buyer of stock by $139M.
- Logos Global Management has $1.7B in assets under management (AUM), dropping by 48.34%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 67 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines Call Option (RVMD) | 14.4 | $239M | +9% | 3.0M | 79.65 |
|
| Ideaya Biosciences (IDYA) | 7.5 | $124M | +32% | 3.6M | 34.57 |
|
| Praxis Precision Medicines I Com New (PRAX) | 6.7 | $111M | +200% | 375k | 294.74 |
|
| Olema Pharmaceuticals (OLMA) | 4.8 | $80M | 3.2M | 25.00 |
|
|
| Cidara Therapeutics Com New (CDTX) | 4.1 | $69M | -17% | 310k | 220.89 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.3 | $54M | -3% | 400k | 134.85 |
|
| Erasca (ERAS) | 2.9 | $48M | -14% | 13M | 3.72 |
|
| Ocular Therapeutix (OCUL) | 2.6 | $43M | +7% | 3.5M | 12.14 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.5 | $42M | -29% | 600k | 69.55 |
|
| Disc Medicine (IRON) | 2.4 | $41M | +13% | 510k | 79.41 |
|
| Maze Therapeatics (MAZE) | 2.4 | $39M | -22% | 950k | 41.43 |
|
| Tango Therapeutics (TNGX) | 2.2 | $37M | +342% | 4.2M | 8.86 |
|
| Avidity Biosciences Ord (RNA) | 2.2 | $36M | -16% | 500k | 72.13 |
|
| Biogen Idec (BIIB) | 2.1 | $35M | +100% | 200k | 175.99 |
|
| Immunovant (IMVT) | 2.1 | $35M | +400% | 1.4M | 25.42 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.1 | $34M | 200k | 170.00 |
|
|
| Terns Pharmaceuticals (TERN) | 1.8 | $30M | NEW | 750k | 40.40 |
|
| Vaxcyte (PCVX) | 1.8 | $30M | +4% | 650k | 46.14 |
|
| Immunocore Hldgs Ads (IMCR) | 1.8 | $30M | 850k | 34.71 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.6 | $27M | +6% | 1.2M | 22.26 |
|
| Apellis Pharmaceuticals Call Option (APLS) | 1.5 | $25M | 1.0M | 25.12 |
|
|
| Arcus Biosciences Incorporated Call Option (RCUS) | 1.5 | $25M | NEW | 1.1M | 23.83 |
|
| Dyne Therapeutics (DYN) | 1.5 | $25M | -47% | 1.3M | 19.56 |
|
| Design Therapeutics (DSGN) | 1.4 | $24M | -31% | 2.5M | 9.38 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.4 | $23M | NEW | 1.8M | 13.18 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.4 | $23M | NEW | 850k | 26.71 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $20M | -5% | 190k | 107.04 |
|
| Trevi Therapeutics (TRVI) | 1.2 | $19M | -29% | 1.6M | 12.52 |
|
| Cytokinetics Com New (CYTK) | 1.2 | $19M | NEW | 300k | 63.54 |
|
| Mirum Pharmaceuticals (MIRM) | 1.1 | $18M | NEW | 225k | 78.99 |
|
| Uniqure Nv SHS (QURE) | 1.0 | $16M | +125% | 675k | 23.93 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $16M | NEW | 450k | 35.08 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.9 | $14M | NEW | 350k | 41.25 |
|
| Soleno Therapeutics (SLNO) | 0.8 | $14M | NEW | 300k | 46.30 |
|
| Janux Therapeutics (JANX) | 0.8 | $14M | -30% | 1.0M | 13.80 |
|
| Minerva Neurosciences Com New (NERV) | 0.8 | $13M | NEW | 3.3M | 4.02 |
|
| Verastem Com New (VSTM) | 0.8 | $13M | -58% | 1.7M | 7.72 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $13M | +57% | 315k | 41.21 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.7 | $12M | -34% | 950k | 12.08 |
|
| Kymera Therapeutics (KYMR) | 0.6 | $10M | -48% | 130k | 77.81 |
|
| Celldex Therapeutics Com New (CLDX) | 0.6 | $9.5M | NEW | 350k | 27.16 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $9.5M | NEW | 500k | 18.97 |
|
| Immatics SHS Call Option (IMTX) | 0.5 | $8.9M | NEW | 850k | 10.50 |
|
| Cg Oncology (CGON) | 0.5 | $8.3M | NEW | 200k | 41.52 |
|
| Arcellx Common Stock (ACLX) | 0.5 | $7.5M | -30% | 115k | 65.20 |
|
| Crescent Biopharma (CBIO) | 0.4 | $7.1M | 600k | 11.86 |
|
|
| Compass Therapeutics (CMPX) | 0.4 | $6.2M | -43% | 1.2M | 5.37 |
|
| Jade Biosciences Com New (JBIO) | 0.4 | $6.1M | -36% | 395k | 15.43 |
|
| Tyra Biosciences (TYRA) | 0.3 | $5.5M | NEW | 210k | 26.29 |
|
| Enliven Therapeutics (ELVN) | 0.3 | $5.2M | 340k | 15.40 |
|
|
| Immix Biopharma (IMMX) | 0.3 | $5.2M | NEW | 1.0M | 5.23 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.3 | $5.0M | -61% | 200k | 25.01 |
|
| Neurogene (NGNE) | 0.2 | $4.0M | NEW | 195k | 20.60 |
|
| Ibio Com New (IBIO) | 0.2 | $3.9M | NEW | 2.0M | 1.93 |
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $3.9M | NEW | 500k | 7.70 |
|
| Oric Pharmaceuticals (ORIC) | 0.2 | $3.7M | NEW | 450k | 8.18 |
|
| Day One Biopharmaceuticals I (DAWN) | 0.2 | $2.8M | NEW | 300k | 9.32 |
|
| Pharvaris N V (PHVS) | 0.2 | $2.8M | -33% | 100k | 27.75 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.2 | $2.7M | 474k | 5.77 |
|
|
| Fractyl Health (GUTS) | 0.1 | $2.4M | +120% | 1.1M | 2.20 |
|
| Palatin Technologies Com New (PTN) | 0.1 | $2.2M | NEW | 140k | 15.38 |
|
| Aclaris Therapeutics (ACRS) | 0.1 | $1.8M | -60% | 600k | 3.01 |
|
| Vor Biopharma Com New (VOR) | 0.1 | $1.3M | NEW | 100k | 13.08 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.0 | $771k | +270% | 1.9M | 0.42 |
|
| Septerna (SEPN) | 0.0 | $657k | -71% | 24k | 27.88 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.0 | $479k | NEW | 25k | 19.17 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $22k | 67k | 0.33 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2025 Q4 filed Feb. 17, 2026
- Logos Global Management 2025 Q3 filed Nov. 14, 2025
- Logos Global Management 2025 Q2 filed Aug. 14, 2025
- Logos Global Management 2025 Q1 filed May 15, 2025
- Logos Global Management 2024 Q4 filed Feb. 14, 2025
- Logos Global Management 2024 Q3 filed Nov. 14, 2024
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022
- Logos Global Management 2022 Q2 filed Aug. 15, 2022